Name: Carfilzomib
Alias: Carfilzomib (PR-171); (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide; Carfilzomib; Kyprolis; UNII-72X6E3J5AR;
CAS No.: 868540-17-4
Molecular formula: C40H57N5O7
Molecular weight: 719.91000
Molecular weight:719.42600
PSA: 158.47000
LogP: 4.08500
Carfilzomib is a second-generation proteasome inhibitor used in oncology. Its core synthesis involves complex peptide coupling and oxirane ring formation. Molecular Formula: C29H40N6O8; CAS No.: 517222-86-1.
Requires strict temperature control (stored at -20°C). Clinical use demands monitoring for cardiac toxicity and hypertension. Administer only under specialized medical supervision.